

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Date: 14th November, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcomes of Board Meeting and Un-Audited Financial Results (Standalone) for the Quarter and Six Months ended 30th September, 2023

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and Six Months ended 30th September, 2023 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

Further, in Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that Board of Directors of Genomic Valley Biotech Limited at their meeting held today has considered and approved following matters also:

1. Resignation of Mrs. Parul Agrawal (DIN: 01165188) from the post of Non-Executive (Non-Independent) Director of the Company with effect from the closing of business hours of 14th November, 2023.
2. Appointment of Mr. Ashok Kumar (DIN: 07647876) as an Additional Non-Executive (Non-Independent) Director on the Board with effect from 14th November, 2023.
3. Reconstitution of Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and Risk Management Committee pursuant to resignation and appointment of Directors/KMP.

The requisite disclosure as required as per the requirement of Regulation 30 read with Schedule III, Para A, Clause (7B) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are given as Annexure-A.

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 05:00 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Anupam Aditya
Company Secretary & Compliance Officer
M. No.: A60613

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Statement of Un-Audited Financial Results for the quarter ended 30/09/2023 and Year to date from 01/04/2023 to 30/09/2023

In Rs.

| Sr. No. | Particular | 3 months ended | Preceding 3 months ended | Corresponding 3 months ended in the previous year | Year to date figures for current period ended | Year to date figures for corresponding period ended | Previous year ended |
|---------|--|----------------|--------------------------|---|---|---|---------------------|
| | | 30-Sep-23 | 30-Jun-23 | 30-Sep-22 | 30-Sep-23 | 30-Sep-22 | 31-Mar-23 |
| | | Un-Audited | Un-Audited | Un-Audited | Un-Audited | Un-Audited | Audited |
| I | Revenue From Operations | 675,250 | 585,500 | 205,000 | 1,260,750 | 10,543,000 | 27,225,190 |
| II | Other Income | - | 15,002 | 80,000 | 15,002 | 224,877 | 425,453 |
| III | Total Revenue (I+II) | 675,250 | 600,502 | 285,000 | 1,275,752 | 10,767,877 | 27,650,643 |
| IV | Expenses | | | | | | |
| | Cost of materials consumed | - | - | - | - | - | - |
| | Purchases of Stock-in-Trade | - | - | - | - | 9,817,600 | 15,836,800 |
| | Changes in inventories of finished goods work-in-progress and Stock-in-Trade | - | - | - | - | - | - |
| | Employee benefits expense | 90,000 | 195,000 | 151,610 | 285,000 | 977,097 | 1,496,087 |
| | Financial costs | - | - | - | - | - | - |
| | Depreciation and amortization expense | 2,731 | 2,731 | 76,324 | 5,462 | 152,648 | 79,243 |
| | Other expenses | 350,380 | 134,666 | 367,420 | 485,045 | 642,969 | 1,106,730 |
| | Total Expenses (IV) | 443,111 | 332,397 | 595,354 | 775,507 | 11,590,314 | 18,518,860 |
| V | Profit/ (Loss) before exceptional item and tax (III-IV) | 232,139 | 268,105 | -310,354 | 500,244 | -822,437 | 9,131,783 |
| VI | Exceptional Item | - | - | 925,000 | - | 6,029,788 | 2,643,164 |
| VII | Profit/loss before Tax (V-VI) | 232,139 | 268,105 | 614,646 | 500,244 | 5,207,351 | 6,488,619 |
| VIII | Tax expenses | | | | | | |
| | (1) Current Tax | - | - | - | - | - | - |
| | (2) Deferred Tax | - | - | - | - | - | 6,080 |
| IX | Profit/ (Loss) for the period from continuing operations (VII-VIII) | 232,139 | 268,105 | 614,646 | 500,244 | 5,207,351 | 6,482,539 |
| X | Profit/ (Loss) from discontinued operations | - | - | - | - | - | - |
| XI | Tax expense of discontinued operations | - | - | - | - | - | - |
| XII | Profit/ (Loss) from discontinuing operations (after tax) (X-XI) | - | - | - | - | - | - |
| XIII | Profit/Loss for the period (IX+XII) | 232,139 | 268,105 | 614,646 | 500,244 | 5,207,351 | 6,482,539 |

Kamran



| | | | | | | | |
|-------|---|-----------|-----------|-----------|-----------|-----------|-----------|
| XIV | Other Comprehensive Income | | | | | | |
| A | (i) Items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| B | (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |
| XV | Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period) | 232,139 | 268,105 | 614,646 | 500,244 | 5,207,351 | 6,482,539 |
| XVI | Paid up Equity Share Capital, Equity Share of ₹ 10/- each | 3,054,500 | 3,054,500 | 3,054,500 | 3,054,500 | 3,054,500 | 3,054,500 |
| XVII | Earning Per Equity Share (for continuing operation): | | | | | | |
| | 1) Basic | 0.08 | 0.09 | 0.20 | 0.16 | 1.70 | 2.12 |
| | 2) Diluted | 0.08 | 0.09 | 0.20 | 0.16 | 1.70 | 2.12 |
| XVIII | Earning Per Equity Share (for discontinued operation): | | | | | | |
| | 1) Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | 2) Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIX | Earning Per Equity Share (for discontinued & continuing operations): | | | | | | |
| | 1) Basic | 0.08 | 0.09 | 0.20 | 0.16 | 1.70 | 2.12 |
| | 2) Diluted | 0.08 | 0.09 | 0.20 | 0.16 | 1.70 | 2.12 |

Kanup



GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2023

| Particulars | Amount in INR | | |
|--|-----------------|--------------------|-------------------|
| | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| A. CASH FLOW FROM OPERATING ACTIVITIES | | | |
| Net Profit As Statement Profit & Loss | 500,244 | -822,437 | 9,131,783 |
| Adjustment For | | | |
| Discount received | - | - | - |
| Non-Operating Income | - | - | - |
| Interest Income | 15,002 | 224,877 | -425,453 |
| Gain/(Loss) on sale of assets | - | -6,029,788 | - |
| Depreciation and Amortisation Expense s | 5,462 | 152,648 | 79,243 |
| Operating Profit Before Change in Working Capital | 520,708 | -6,474,700 | 8,785,573 |
| | | | |
| ADJUSTMENTS FOR WORKING CAPITAL: | | | |
| Increase/Decrease in Loans and Advances | 4,785,593 | -3,202,389 | -9,350,593 |
| Increase/ Decrease in Inventories | - | - | - |
| Increase/Decrease in Security Deposits | - | - | - |
| Increase/Decrease in Trade Receivables | 11,838,099 | -12,583,900 | -22,174,825 |
| Increase/Decrease in Other Current Assets | -40,438,418 | 9,425,335 | 8,163,222 |
| Increase/Decrease in Current Liabilities | 23,304,537 | -2,358,209 | 6,789,970 |
| CASH GENERATED FROM OPERATIONS | 10,519 | -15,193,863 | -7,786,652 |
| Taxes Paid | | | |
| Total (A) | 10,519 | -15,193,863 | -7,786,652 |
| | | | |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | | |
| Additions/Sales to fixed assets | | 15,504,788 | 14,792,500 |
| Purchase/Sell of Investments | -166,660 | - | - |
| Discount received | - | - | - |
| Non-Operating Income | - | - | - |
| Interest Income | -15,002 | -224,877 | 425,453 |
| Total (B) | -181,662 | 15,279,911 | 15,217,953 |
| | | | |
| C. CASH FLOWS FROM FINANCING ACTIVITIES | | | |
| Proceeds from Borrowings | - | - | -7,045,000 |
| Preliminary Expenses | - | - | - |
| Total (C) | - | - | -7,045,000 |
| | | | |
| NET CASH FLOWS DURING THE YEAR (A+B+C) | -171,142 | 86,048 | 386,301 |
| Cash and Cash Equivalents (Opening Balance) | 413,092 | 26,791 | 26,791 |
| Cash and Cash Equivalents (Closing Balance) | 241,950 | 112,839 | 413,092 |

Kanungo



Statement of Asset and Liabilities as at 30.09.2023

| Particulars | Current half year ended | Previous year ended |
|--------------------------------------|--------------------------|-----------------------|
| | 30/09/2023 | 31/03/2023 |
| | Un-Audited Standalone | Audited Standalone |
| ASSETS | | |
| Non Current Assets | | |
| Property, plant and equipment | 26,119 | 31,581 |
| Capital work in progress | | |
| Other Intangible assets | | |
| Intangible assets under development | | |
| Financial assets | | |
| Investment | | |
| Loans | 13,565,000 | 18,350,593 |
| Security Deposits | 50,000 | 50,000 |
| Other financial assets | | |
| Deferred tax assets (Net) | | |
| Other non current assets | | |
| Total Non-Current Assets | 13,641,119 | 18,432,174 |
| Current Assets | | |
| Inventories | | |
| Financial Assets: | | |
| Investments | 166,660 | - |
| Trade Receivables | 10,336,726 | 22,174,825 |
| Cash and Cash equivalents | 2,844 | 2,844 |
| Other Balances with banks | 239,106 | 410,248 |
| Loans | | |
| Other financial assets | | |
| Other Current assets | 43,622,239 | 3,183,821 |
| Total Current Assets | 54,367,575 | 25,771,738 |
| Total Assets | 68,008,694 | 44,203,912 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity Share Capital | 30,545,000 | 30,545,000 |
| Othe Equity | 5,224,026 | 4,723,782 |
| Total Equity | 35,769,026 | 35,268,782 |
| Non Current Liabilities | | |
| Financial liabilities | | |
| Borrowings | | |
| Security Deposits | | |
| Other Financials liabilities | | |
| Deferred tax liabilities (Net) | 2,178 | 2,178 |
| Provisions | | |
| Other Non Current liabilities | | |
| Total Non Current Liabilities | 2,178 | 2,178 |
| Current Liabilities | | |
| Financial liabilities | | |
| Borrowings | | |
| Trade Payables | 6,078,918 | 6,106,203 |
| Other Financials liabilities | | |
| Provisions | 54,000 | 54,000 |
| Other Current liabilities | 26,104,572 | 2,772,749 |
| Total Current Liabilities | 32,237,490 | 8,932,952 |
| TOTAL EQUITY AND LIABILITIES | 68,008,694 | 44,203,912 |

Kanungo



Notes :

- 1 The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on November 14, 2023. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- 2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- 3 Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- 4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



A handwritten signature in blue ink, appearing to read "Yogesh Agrawal".

Yogesh Agrawal
(Chairman & Managing Director)
DIN-01165288
Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 14.11.2023

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter ended on
September 30, 2023 and year to date from April 01, 2023 to September 30, 2023**

We have reviewed the accompanying statement of unaudited financial results for the Quarter ended on September 30, 2023 and year to date from April 01, 2023 to September 30, 2023 ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.
Chartered Accountants



(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

UDIN: 23502310-BGUYXE-8393

Place: Delhi
Date: 14-11-2023

Peer Review:

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Annexure-A

A. Particulars of Resignation of Mrs. Parul Agrawal as Non-Executive (Non-Independent) Director:

| S. No. | Particulars | Details |
|--------|---|--|
| a) | Name of Person | Parul Agrawal |
| b) | Reason for change viz. appointment , resignation, removal, death or otherwise | Mrs. Parul Agrawal (DIN: 01165188) has expressed his intention to resign as Non-Independent Director of the Company with effect from the closing of business hours of 14 th November, 2023 due to his personal reasons, as mentioned in his resignation letter dated 14 th November, 2023. |
| c) | Date of appointment / cessation (as applicable) | 14th November, 2023 |
| d) | Terms of Appointment | N.A |
| e) | Brief profile (in case of appointment) | N.A |
| f) | Disclosure of relationships between directors (in case of appointment of a director) | N.A |
| g) | Letter of Resignation along with detailed reason of resignation | Annexure-B |
| h) | Names of the listed entities in which Mrs. Parul Agrawal holds Directorships, indicating the category of Directorship and Membership of Board Committees. | Directorship: Nil Committee Position: Nil |



GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



B. Particulars of Appointment of Mr. Ashok Kumar (DIN: 07647876) as Additional Non-Executive (Non-Independent) Director:

| S. No. | Particulars | Details |
|---------------|--|--|
| a) | Name of Person | Mr. Ashok Kumar |
| b) | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment as Additional Non-Executive (“Non-Independent Category”) Director |
| c) | Date of appointment / cessation (as applicable) | 14 th November, 2023 |
| d) | Terms of Appointment | Subject to approval of the Shareholders of the Company, by means of a special resolution and Liable to retire by rotation [In accordance with the Companies Act, 2013] |
| e) | Brief profile (in case of appointment) | Mr. Ashok Kumar Graduated in Arts (BA) and having experience of 25+ years in sales and purchase department. |
| f) | Disclosure of relationships between directors (in case of appointment of a director) | No inter-se relationship between the directors. |
| g) | Declaration | We confirm that Mr. Ashok Kumar is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority. |



GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Intimation of Re-constitution of Committees:

Consequent upon resignation of Mrs. Parul Agrawal, the Reconstitution of all the Committees w.e.f. 15th November, 2023 shall be as follows:

Audit Committee

| <u>Name of Committee Members</u> | <u>Category</u> |
|---|---|
| <u>Mr. Praveen Kumar Mishra</u> | <u>Non-Executive and Independent Director, Chairman</u> |
| <u>Mr. Ashok Kumar</u> | <u>Non-Executive – Non-Independent Director, Member</u> |
| <u>Ms. Jyoti Bansal</u> | <u>Non-Executive - Independent Director, Member</u> |

Nomination and Remuneration Committee

| <u>Name of Committee Members</u> | <u>Category</u> |
|---|---|
| <u>Mr. Praveen Kumar Mishra</u> | <u>Non-Executive and Independent Director, Chairman</u> |
| <u>Mr. Ashok Kumar</u> | <u>Non-Executive and Non-Independent Director, Member</u> |
| <u>Ms. Jyoti Bansal</u> | <u>Non-Executive and Independent Director, Member</u> |

Stakeholders Relationship Committee

| <u>Name of Committee Members</u> | <u>Category</u> |
|---|---|
| <u>Mr. Praveen Kumar Mishra</u> | <u>Non-Executive and Independent Director, Chairman</u> |
| <u>Mr. Ashok Kumar</u> | <u>Non-Executive and Non-Independent Director, Member</u> |
| <u>Ms. Jyoti Bansal</u> | <u>Non-Executive and Independent Director, Member</u> |

Risk Management Committee

| <u>Name of Committee Members</u> | <u>Category</u> |
|---|---|
| <u>Mr. Praveen Kumar Mishra</u> | <u>Non-Executive and Independent Director, Chairman</u> |
| <u>Mr. Ashok Kumar</u> | <u>Non-Executive and Non-Independent Director, Member</u> |
| <u>Ms. Jyoti Bansal</u> | <u>Non-Executive and Independent Director, Member</u> |



Date: 14 November, 2023

To
The Board of Director
Genomic Valley Biotech Limited
4 K.M. Stone, Berri Chharra Road Vill. Kherka,
Musalman, P.O. Tandaheri Teh Bahadu Jhajjar HR-124507

Sub: Resignation from the Position of Director

Dear Sir/Madam,

I hereby tender my resignation as Non-Executive Non-Independent Director from the Board of Genomic Valley Biotech Limited due to personal reasons with effect from closing of business hours of 14th November, 2023

I confirm that there are no material reasons other than what is mentioned above for my resignation.

I further confirm that I hold no directorship in any other listed company.

I don't hold any membership and chairmanship in any other listed Company.

I wish to place on record my gratitude and appreciation to my esteemed Board Members for their continuous support and guidance.

It was a privilege to serve as a Board Member of Genomic Valley Biotech Limited.

Kindly acknowledge/ communicate the receipt of this resignation letter and arrange to intimate the Registrar of Companies and Stock Exchange.

Thanking you.



Parul Agrawal
(DIN: 01165188)